TABLE 1.

Efficacy of single-dose AmBisome in L. donovani-infected BALB/c mice^a

Parameter	Dose (mg/kg)	Result for parameter shown
		Liver			Spleen
		Day 21 p.i.	Day 42 p.i.	Significance	Day 21 p.i.	Day 42 p.i.	Significance
% of reduction in parasite burden
Expt 1	10	99 ± 0	98 ± 1	NS	99 ± 0	83 ± 4	P ≤ 0.05
	2.5	78 ± 2	78 ± 5	NS	53 ± 6	5 ± 5	P ≤ 0.0001
	0.6	21 ± 8	41 ± 4	P ≤ 0.01	44 ± 6	4 ± 4	P ≤ 0.0001
Expt 2	2.5	81 ± 2	80 ± 3	NS	71 ± 2	36 ± 11	P ≤ 0.05
Expt 3	10	100 ± 0	99 ± 1	NS	99 ± 0	93 ± 2	NS
	2.5	94 ± 1	80 ± 5	P ≤ 0.05	40 ± 6	45 ± 7	NS
	0.6	54 ± 3	22 ± 7	P ≤ 0.0001	38 ± 10	16 ± 9	NS
Parasite burden (LDU) in untreated control groups
Expt 1	NA	966 ± 66	518 ± 48	P ≤ 0.01	88 ± 8	118 ± 15	NS
Expt 2	NA	415 ± 32	176 ± 11	P ≤ 0.001	18 ± 1	53 ± 8	P ≤ 0.01
Expt 3	NA	682 ± 54	194 ± 44	P ≤ 0.001	18 ± 2	84 ± 9	P ≤ 0.001

^aParasite burden was evaluated 7 days after drug administration on day 21 or 42 postinfection (p.i.). Data are presented as mean ± SEM. NS, not significant; NA, not applicable; LDU, Leishman-Donovan units.